Ibsrela vs Viberzi
A side-by-side look at two gastrointestinal medications advertised on TV. Informational only — not medical advice.
| US Ibsrela | US Viberzi | |
|---|---|---|
| Generic name | tenapanor | eluxadoline |
| Drug class | Sodium/Hydrogen Exchanger 3 (NHE3) Inhibitor | Mu-Opioid Receptor Agonist |
| Treats | Irritable bowel syndrome with constipation (IBS-C) | Irritable bowel syndrome with diarrhea |
| Category | Gastrointestinal | Gastrointestinal |
| Manufacturer | Ardelyx | AbbVie |
| Year approved | 2019 | 2015 |
| FDA warning | Black box warning | Moderate warnings |
| Est. TV ad spend | — | — |
| Common side effects | Diarrhea, Should not be used in young children (boxed warning), Gas, Abdominal pain | Constipation, Nausea, Abdominal pain, Risk of pancreatitis |
Frequently asked questions
Is Ibsrela or Viberzi better?
Neither is universally "better." Ibsrela (tenapanor) and Viberzi (eluxadoline) are both used for gastrointestinal, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Ibsrela and Viberzi?
Ibsrela is a Sodium/Hydrogen Exchanger 3 (NHE3) Inhibitor made by Ardelyx, while Viberzi is a Mu-Opioid Receptor Agonist made by AbbVie. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Ibsrela has the larger estimated TV advertising budget of the two.